Form 8-K Mirati Therapeutics, For: Dec 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Citi Downgrades Mirati Therapeutics (MRTX) to Neutral
December 8, 2022 8:22 AM ESTCiti analyst Yigal Nochomovitz downgraded Mirati Therapeutics (NASDAQ: MRTX) from Buy to Neutral with a price target of $53.00 (from $121.00).
The analyst comments "We recognize MRTXs new meta-analysis suggests the bar in 1L G12C NSCLC is lower than we previously believed (wed cited a ~63-67%... More
Jefferies Reiterates Buy Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:01 AM ESTJefferies analyst Maury Raycroft reiterated a Buy rating and $149.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Abstract data strengthen adagrasib's 1L pembro combo profile, removing worst-case scenarios and showing positive differentiation on safety+efficacy vs AMGN. MRTX said we'll... More
Piper Sandler Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTPiper Sandler analyst Swapnil Malekar reiterated an Overweight rating and $110.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO abstract revealed that adagrasib+pembro combo in 1L NSCLC patients showed an ORR of 49%, which came in below the Street expectation of ~55%... More
JPMorgan Reiterates Overweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 8:00 AM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $94.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "ESMO-IO late-breaking abstracts were published this evening, including an updated look at the phase 2 KRYSTAL-7 trial (adagrasib + pembrolizumab in 1L G12C+ NSCLC). On the whole, we believe the data continue to support the regimens differentiated positioning relative to standard of care and are far more favorable than that of Lumakras + CPI.... More
Morgan Stanley Reiterates Equalweight Rating on Mirati Therapeutics (MRTX)
December 6, 2022 7:59 AM ESTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)
The analyst comments "Data in the abstract from the Ph2 K-7 study (adagrasib + pembro) in 1L NSCLC confirm a tolerable safety profile, as expected. That... More
